NephrologyNow The Ultimate Guide to Kidney Disease Research

Interventions for bone disease in children with chronic kidney disease.

Geary DF, Hodson EM, Craig JC.   Cochrane Database Syst Rev.   2010 Jan 20;(1):CD008327

This systematic review of interventions for bone disease in children with CKD concludes that all examined vitamin D formulations reduce PTH levels and that sevelamer as compared to calcium-based binders reduced serum calcium and hypercalcemic events. However, no reduction in hard clinical endpoints was identified.

• 

Oral Phosphate Binders in Patients with Kidney Failure

Tonelli M, Pannu N, Manns B.   N Engl J Med.   2010 Apr 8;362(14):1312-24

This concise review discusses the rationale for the use of phosphate binders in kidney disease and summarizes therapeutic strategies.

• 

Second Chances in Mineral Metabolism

Wolf M.   Clin J Am Soc Nephrol.   2010 Jan;5(1):1-3

In this succinct editorial, Dr. Wolf reinforces the rationale for performing proper randomized controlled trials in bone mineral metabolism before changing clinical practice.  In addition, he provides insight into a first-in-class substudy of the ACHIEVE study which looks at the effects of cinacalcet and activated Vitamin D on FGF23 levels in ESRD. Free full text [...]

• 

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD)

These clinical practice guidelines developed by KDIGO are designed to address the diagnosis, evaluation, prevention and treatment of CKD related disorders of bone mineral metabolism.

• 

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G.   J Am Soc Nephrol.   2009 Mar;20(3):639-44

• 

Salivary phosphorus binding: a novel approach to control hyperphosphatemia.

Eknoyan G.   J Am Soc Nephrol.   2009 Mar;20(3):460-2

• 

Effect of Food Additives on Hyperphosphatemia Among Patients With End-stage Renal Disease A Randomized Controlled Trial.

Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR.   JAMA.   2009 Feb 11;301(6):629-35

• 

Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K.   J Am Soc Nephrol.   2008 Nov;19(11):2193-203

• 

Oral active vitamin D is associated with improved survival in hemodialysis patients.

Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB.   Kidney Int.   2008 Oct;74(8):1070-8

• 

Vitamin D in chronic kidney disease: is the jury in?

de Boer IH, Kestenbaum B.   Kidney Int.   2008 Oct;74(8):985-7

• 

Association of oral calcitriol with improved survival in nondialyzed CKD.

Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B.   J Am Soc Nephrol.   2008 Aug;19(8):1613-9

• 

Active vitamin D and survival.

Wolf M.   J Am Soc Nephrol.   2008 Aug;19(8):1442-3

• 

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW.   Clin J Am Soc Nephrol.   2008 Jul;3(4):1131-8

•